Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04482374 · ClinicalTrials.gov registry record
Puberty Suppression and Cardiometabolic Health
A clinical trial of Endothelial Dysfunction and Vascular Stiffness, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04482374: Recruiting study of Endothelial Dysfunction and Vascular Stiffness, sponsored by University of Colorado, Denver.
NCT04482374 is a study of Endothelial Dysfunction and Vascular Stiffness that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 30 participants, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04482374, a study of Endothelial Dysfunction and Vascular Stiffness, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.
Primary Outcome
Insulin sensitivity assessed by the oral minimal model
Conditions Studied
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2026-07-31 |
What NCT04482374 shows while recruiting
NCT04482374 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (67% lower).
The record links to 4 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 0 interventions.
NCT04482374 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT04482374 about?
NCT04482374 is a clinical study titled "Puberty Suppression and Cardiometabolic Health". This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.
What is the current status of trial NCT04482374?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2020-08-10. Estimated completion is 2026-07-31.
What conditions does trial NCT04482374 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Vascular Stiffness, Transgenderism, Insulin Sensitivity/Resistance.
Who is sponsoring clinical trial NCT04482374?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04482374 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04482374's enrollment target sits among peer trials
30 31st of 45 higher than 13 of 45 other Endothelial Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endothelial Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
Role of Endothelial Function in SCI CVD Risk
RECRUITING
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
B-Complex: A Nutraceutical SANS Countermeasure
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI